Omeros Corporation (OMER) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

  • Good afternoon and welcome to today's earnings call for Omeros Corporation.

  • (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be available on the company's website.

  • I will now turn the call over to Jennifer Williams, Investor Relations for Omeros. Please go ahead.

  • Jennifer Williams - Investor Relations, Media Relations

  • Thank you and good afternoon, everyone.

  • Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs, as of today; and are subject to risks and uncertainties that could cause actual results to differ materially.

  • For a detailed discussion of these risks and uncertainties, please refer to the SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS and the RISK FACTORS sections in our quarterly report on Form 10-Q, filed today with the SEC, as well as our most recent annual report on Form 10-K.

  • Today's call will also include a discussion of certain non-GAAP financial measures.

  • A reconciliation of these non-GAAP measures to the corresponding GAAP measures is included in Omeros' earnings press release, issued earlier today, which is available on the Investor Relations page of our website and has been furnished with the Form 8-K we filed with the SEC earlier today.

  • With that, I'll turn the call over to Dr. Greg Demopulos, Chairman and CEO of Omeros.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Thank you, Jennifer. And, good afternoon, everyone.

  • Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; Dr. Steve Whitaker, Vice President of Clinical; and Bill Woodman, our Chief Commercial Officer.

  • I'll begin with an overview of our third-quarter operations and financial results, followed by program updates. David will then review the financials in more detail. After which, we'll open the call for questions.

  • Following FDA approval in December 2025, we launched YARTEMLEA in late January as the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy or TA-TMA.

  • YARTEMLEA is also the first and only approved inhibitor of the lectin pathway of complement.

  • The third quarter marked just our second full quarter of YARTEMLEA sales. And we're pleased with our progress.

  • In the third quarter, YARTEMLEA generated $41.8 million in gross sales and $35.9 million in net sales, reflecting continued commercial momentum.

  • Compared with the second quarter, gross sales increased 30% and net sales increased 26%.

  • As expected, gross-to-net deductions increased to 14% of gross sales from 11.5% in the second quarter, driven almost entirely by a substantial increase in 340B sales, consistent with our goals of increasing outpatient utilization of YARTEMLEA and expanding our customer base.

  • That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.

  • As discussed in prior earnings calls, our reported GAAP financial results include mandatory non-cash mark-to-market adjustments associated with the embedded derivative in our 2029 convertible notes.

  • A higher Omeros stock price increases the related non-cash expense. Reflecting these non-cash adjustments, GAAP net loss for the third quarter was $57.4 million or $0.79 per share compared to net income of $13.2 million or $0.18 per share in the second quarter.

  • Excluding the non-cash remeasurements of the embedded derivatives and other financial instruments, non-GAAP adjusted net income for the third quarter was $4.7 million or $0.06 per share compared to second-quarter net income of $1.8 million or $0.02 per share.

  • We ended the third quarter with $95.3 million in cash and investments. Most importantly, we generated $13.3 million in net cash from operating activities during the quarter, marking our second consecutive quarter of positive operating cash flow.

  • As a reminder: In July, we repurchased $30.5 million in aggregate principal amount of our 2029 convertible notes through two privately negotiated transactions for an aggregate of $60.2 million, reducing the outstanding principal amount by 43% to $40.3 million.

  • These transactions also reduced potential dilution by 4.9 million shares and eliminated $8.6 million in future interest payments. We achieved this reduction at a weighted average cost of $12.21 per underlying conversion share.

  • Including the repurchase of a little over 843,000 shares of common stock in the open market at $11.70 per share during the first half of 2026, we have reduced the number of outstanding or potentially issuable shares by 5.8 million year to date.

  • Let's now look more closely at our YARTEMLEA launch. As we have discussed before, our launch is focused on four priorities:

  • One, educating transplant teams to recognize and treat TA-TMA earlier; two, securing institutional access through pharmacy and therapeutics or [P&T] committee approvals and streamlined ordering; three, ensuring timely and appropriate reimbursement and helping centers understand YARTEMLEA's reimbursement advantages over off-label therapies; and, four, demonstrating YARTEMLEA's economic value through health economics and outcomes research or [HEOR].

  • Through these four priorities, we continue our work to shift clinical practice toward proactive screening for TA-TMA, rather than defaulting to a diagnosis of exclusion; and toward earlier identification and treatment of more patients, with the goal of improving outcomes.

  • To continue advancing these priorities, we have expanded our educational team by adding members to our market-development management and medical-science liaison teams.

  • This expansion will further strengthen our field medical and educational capabilities and support scientific engagement with healthcare professionals across transplant centers, nationwide.

  • In addition to physicians and pharmacists, we remain focused on supporting nurses. Nurses spend the most time with transplant patients and are often the first care-team members to notice changes suggestive of TA-TMA.

  • For this reason, we recently established a clinical-nurse educator team of six nurses from top-tier transplant centers. These Omeros nurses will work directly with nurses in transplant centers across the country.

  • Transplant centers have large nursing teams. And staff turn-over, new hires, and rotating assignments create an ongoing need for training to reinforce recognition of the signs and symptoms of TA-TMA.

  • Our nurse educators will help make TA-TMA awareness part of everyday-transplant care, supporting more consistent identification and timely treatment with YARTEMLEA.

  • So, across our nurse educators, market-development managers, and medical-science liaisons, we have added a total of 10 positions to our field-force educational team.

  • To further support our educational efforts, we are adding to our transplant physician, pharmacist, and nursing-speaker programs by establishing a nephrology-speaker bureau comprising both onco-nephrologists and general nephrologists.

  • Nephrologists are actively involved in the diagnosis and management of TA-TMA. Kidney disease is the most common form of organ dysfunction in TA-TMA.

  • Nephrologists are becoming increasingly well-versed in the role of the lectin pathway. And we expect the nephrology-speaker bureau will meaningfully expand our educational reach, while strengthening understanding of both YARTEMLEA and lectin-pathway biology.

  • Alongside these educational efforts, our field-sales team is actively engaging all 175 US transplant centers. As of September 30, 109 unique accounts had ordered YARTEMLEA, a 49% increase from 73 accounts at June 30.

  • Following an outsized share of pediatric utilization in the first quarter, adult adoption accelerated in the second and third quarters.

  • Adult patients now account for approximately 70% of utilization. And pediatric patients, for 30%. This mix continues to move toward the historical nationwide allogeneic transplant mix of 85%, adult; and 15%, pediatric procedures.

  • As previously discussed, outpatient use of YARTEMLEA also increased this quarter, as evidenced by greater 340B participation.

  • This is good for patients, likely reflective of earlier treatment and, potentially, better outcomes.

  • This is also good for transplant centers, given that reimbursement for approved drugs in the outpatient setting can range from average selling price, or [ASP], plus 4.3% to ASP plus 10% or more.

  • P&T committee approvals also increased by 25% across transplant centers nationwide during the third quarter. By September 30, YARTEMLEA had received P&T committee approvals at 80% of the top 40 US transplant centers, nationwide.

  • Let's turn, now, to reimbursement and the payer experience. To date, all appropriate claims -- of which, we are aware -- have been paid by commercial payers -- Medicare, or Medicaid -- and coverage is fully aligned with the product label.

  • And transplant centers are becoming increasingly aware of the New Technology Add-On Payment, or NTAP, for YARTEMLEA, which became effective on October 1.

  • The NTAP provides up to $287,000 in additional Medicare reimbursement per eligible inpatient case involving YARTEMLEA. This is particularly important because Medicare beneficiaries represent approximately 30% of all US allogeneic transplant recipients.

  • No off-label treatment for TA-TMA, whether branded or biosimilar, has an NTAP. This gives YARTEMLEA a distinct reimbursement advantage that can substantially reduce hospitals' net cost of treating eligible Medicare inpatients.

  • YARTEMLEA's pass-through status also provides an important reimbursement advantage in the Medicare hospital outpatient setting. The Centers for Medicare & Medicaid Services, or CMS, recently issued a new rule on 340B reimbursement.

  • Beginning Jan 1, 2027, Medicare will generally reimburse affected hospitals for 340B-acquired drugs at average sales price, or ASP, minus 28%. Drugs with transitional pass-through status, however, are exempt from this change and will continue to be reimbursed at ASP plus 6% or ASP plus 4.3% after sequestration.

  • Neither branded eculizumab nor ravulizumab has pass-through status. YARTEMLEA holds pass-through status through June 2029 and is, therefore, excluded from this reimbursement reduction.

  • This preserves a substantial reimbursement advantage for YARTEMLEA over these branded off-label treatments, when purchased under the 340B program and administered in affected Medicare hospital outpatient settings.

  • In the outpatient setting for commercially insured patients, YARTEMLEA's higher price per dose also translates into greater dollar margins per dose than lower-priced off-label alternatives, whether branded or biosimilar.

  • We believe YARTEMLEA offers better efficacy and safety than off-label treatments for TA-TMA. These reimbursement advantages provide centers with additional financial incentives to use YARTEMLEA in both inpatient and outpatient settings.

  • Our HEOR manuscript is being finalized, with journal submission planned within the next few weeks. The analyses show favorable incremental cost-effectiveness ratios, or ICERs, for YARTEMLEA compared to best supportive care, eculizumab, and ravulizumab.

  • We expect that these analyses will further demonstrate YARTEMLEA's clinical and economic value, supporting its continued adoption.

  • The recognition of YARTEMLEA's importance to patients and the patient-advocacy community is growing. In September, the National Organization for Rare Disorders, or NORD, honored Omeros with its 2026 Industry Innovation Award for YARTEMLEA. NORD is the nation's leading rare-disease patient-advocacy organization.

  • We are also preparing for a strong presence at the upcoming annual congress of the American Society of Hematology, a major international meeting for hematologists and transplant physicians.

  • Dr. Christine Duncan, Associate Professor at Harvard Medical School and Senior Physician at Dana-Farber Cancer Institute, will give a podium presentation on the consistent response to YARTEMLEA across three cohorts, totaling 71 adult and pediatric patients, with high-risk TA-TMA.

  • Omeros is also sponsoring a continuing medical-education session titled Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant, chaired by Dr. Michelle Schoettler, Associate Professor at Emory University School of Medicine and a pediatric hematologist at Children's Healthcare of Atlanta.

  • The session will examine how TA-TMA has evolved from a historically under-recognized complication with limited treatment options to a disease with increasingly standardized diagnostic criteria, a clearer understanding of its complement biology, and, now, an FDA-approved therapy.

  • The list of YARTEMLEA publications continues to expand:

  • Last month, in the journal Bone Marrow Transplantation, a group of international experts reported on a series of severely ill patients with high-risk TA-TMA -- all of whom required intensive-care unit stays. Responses to YARTEMLEA among these patients were remarkable.

  • Seven other manuscripts associated and authored by transplant physicians are in preparation or have been submitted, detailing similarly impressive responses to narsoplimab treatment in their patients, including the resolution of organ dysfunction and discontinuation of the need for dialysis.

  • It is gratifying to see this growing body of evidence in both adult and pediatric TA-TMA. And supporting these publication efforts remains a corporate priority.

  • Increasing awareness and earlier identification of TA-TMA, nationwide, spurred, in part, by our team's focused educational efforts and growing use and support of YARTEMLEA within the transplant-care community bode well for its adoption as standard of care.

  • Alongside our US-commercial efforts, we are diligently working to expand access internationally. Our initial focus was Europe.

  • As announced in October, the Committee for Medicinal Products for Human Use, or CHMP, following re-examination, which included meetings with CHMP and an Ad Hoc Expert Group, or AHEG, issued a negative opinion on our marketing-authorization application for narsoplimab for the treatment of TA-TMA.

  • CHMP's process and decision were disappointing and, from our perspective, misguided.

  • Separately, due to increasing demand for YARTEMLEA in the US-commercial market, we informed CHMP that, after 10 years of supplying free drug to Europe and other regions globally under compassionate use, we intend to close the YARTEMLEA compassionate-use program to new patients.

  • TA-TMA patients currently receiving YARTEMLEA through the program will be provided sufficient drug to complete their treatment courses.

  • Our regulatory efforts are currently focused outside the European Union, as we work to obtain near-term approvals for YARTEMLEA in TA-TMA across a number of other countries whose regulatory bodies recognize and can build upon the drug's FDA approval.

  • In parallel, we are working to make YARTEMLEA accessible internationally through fully reimbursed named patient programs in parts of Europe and other regions.

  • While pursuing new markets for YARTEMLEA in TA-TMA, we are keenly focused on expanding its indications beyond TA-TMA. Too often, YARTEMLEA is narrowly thought of as a TA-TMA therapeutic. That understates YARTEMLEA's potential.

  • And here's why: Endothelial injury is central to TA-TMA. Endothelial injury and other cellular damage directly activates the lectin pathway. So, YARTEMLEA, as a lectin -pathway inhibitor, has the potential to treat a wide spectrum of disorders driven by endothelial injury.

  • These include other transplant-related disorders, such as veno-occlusive disease, capillary leak syndrome, diffuse alveolar hemorrhage, and graft-versus-host disease.

  • There is substantial interest among transplanters to evaluate YARTEMLEA across these and other indications through investigator-initiated trials.

  • To guide this expansion, we have built a new product-planning team that brings insights from clinicians, health systems, payers, and patients into our pipeline strategy and related clinical-investment decisions.

  • The three-person team will help identify development opportunities with the strongest clinical and commercial potential to build long-term shareholder value.

  • Two open-label, single-arm clinical studies with historical controls evaluating YARTEMLEA are also slated to begin at the end of this year or early next, depending on the timing of Institutional Review Board and ethics-committee approvals.

  • One is in acute respiratory distress syndrome, or ARDS, in which endothelial injury is thought to be a key driver of disease. Mortality is high. And there currently is no good treatment for ARDS, which, each year, affects approximately 190,000 patients in the US alone.

  • The study will assess YARTEMLEA in hyperinflammatory ARDS, which represents about 35% of all ARDS patients.

  • The second will assess YARTEMLEA's ability to prevent TA-TMA in high-risk pediatric-transplant patients. Each study is designed to enroll approximately 50 to 60 patients.

  • Beyond YARTEMLEA, we are advancing the other assets in our MASP-2 platform: our Phase 2-ready long-acting MASP-2 antibody, OMS1029; and our oral MASP-2 small-molecule program.

  • Both are well-suited for chronic indications, with OMS1029 administered once quarterly, intravenously or subcutaneously; and our oral agent targeting once-daily dosing.

  • Where possible, we target an orphan indication that includes a pediatric component as the first indication for a new molecule, potentially qualifying for a valuable rare-pediatric priority review voucher upon FDA approval, subject to the program's eligibility and timing requirements.

  • We are finalizing the initial Phase 2 indication for once-quarterly OMS1029. And clinical drug product and matching placebo have been manufactured and are available for Phase 2 clinical trials.

  • Moving on from our MASP-2 platform, we expect our MASP-3 inhibitor program, the other part of our complement franchise, to generate additional revenue soon.

  • Our collaboration with Novo remains on track. At the closing of the transaction in late 2025, we received an upfront payment of $240 million.

  • In addition, we remain eligible for more than $1.8 billion in development and commercial milestones, including $100 million in near-term milestone payments, plus tiered royalties on net sales.

  • We continue to provide transition services to Novo at Novo's cost and expect to complete those services by mid-2027. In the meantime, we continue to advance our MASP-3 small-molecule program toward the clinic.

  • Let's now turn to our pipeline programs beyond our complement inhibitor franchise:

  • Our PDE7 inhibitor program evaluating OMS527 for cocaine-use disorder remains fully funded by a grant from the National Institute on Drug Abuse, or NIDA.

  • Earlier this year, we met with FDA regarding the agency's request for additional non-clinical information before initiating the inpatient study in cocaine users. That non-clinical work is underway and expected to be completed this month.

  • The contract-research organization conducting the non-clinical study faced delays in acquiring the study animals so we now expect to begin enrollment in the inpatient clinical trial in early 2027, following the upcoming holidays. We still expect data from the clinical trial in 2027.

  • Based on its mechanism of action and our extensive pre-clinical data, we believe that OMS527 could be effective across a wide range of addiction and compulsive disorders.

  • Our Targeted Complement Activating Therapy, or T-CAT platform, is a novel class of recombinant, engineered antibodies, designed to target and directly kill pathogens, including bacteria, fungi, viruses, and parasites.

  • Now, these antibodies initiate complement activation directly on pathogen surfaces, thereby completely bypassing the classical pathway-initiation complex, which pathogens typically exploit to escape immune clearance.

  • Our initial focus is multidrug-resistant organisms, or MDROs, which pose a critical unmet medical need. Unlike conventional antimicrobials, T-CAT is designed to eradicate pathogens, regardless of resistance profile, without promoting new-drug resistance.

  • In translationally relevant murine models of sepsis and pneumonia caused by multiple drug-resistant bacterial species, a single dose of the respective T-CAT monoclonal antibody demonstrated complete protection and bacterial clearance.

  • IND-enabling studies have begun. And we look forward to advancing T-CAT into the clinic.

  • Lastly, OncotoX-AML, or OMS805, is the lead program in our oncology platform. OMS805 is an engineered biologic developed to treat acute myeloid leukemia, or AML, the most common and deadliest acute leukemia in adults.

  • In both in vitro studies and studies in tumor-bearing animal models across a diverse range of human AML cell lines, OMS805 consistently demonstrated superior efficacy compared to current standard-of-care treatments.

  • This potent anti-tumor activity occurs even at very low doses and across mutations, such as those in TP53 and FLT3, which, historically, have been associated with poor outcomes and treatment resistance.

  • In immunocompetent non-human primates, a single course of OncotoX-AML achieved a selective, reversible, and dose-dependent reduction in target myeloid progenitor cells by up to 99%.

  • OncotoX-AML was well tolerated, demonstrating an encouraging safety profile that preserved essential hematopoietic stem cells without causing broader hematologic toxicity.

  • To support upcoming clinical development, process engineering and initial clinical-scale manufacturing are already underway.

  • We have partnered with a leading contract-biologics manufacturer to secure initial clinical-drug supply and support clinical entry, as IND-enabling studies conclude.

  • Working with our Advisory Board of leading AML experts, we are preparing for a first-in-human trial targeted for late 2027.

  • As previously discussed, we are advancing OMS805 in stealth mode and do not plan to provide regular updates. We expect to announce the start of the Phase 1b trial and share clinical data, when available.

  • That concludes our corporate and development-program update.

  • Before moving on to our financial discussion, I would like to welcome Joe Schocken, who joined our Board of Directors and Audit Committee in August.

  • Joe brings decades of experience in investment banking, business leadership, and economic policy. He founded Seattle-based investment bank Broadmark Capital and co-founded and chaired publicly traded Broadmark Realty Capital.

  • A major contributor to the JOBS Act, Joe was also appointed by President Obama to the National Advisory Council on Innovation and Entrepreneurship.

  • We look forward to benefiting from his capital-markets expertise, his business experience, and his policy perspective.

  • Now, with that, I will turn the call over to David Borges, our Chief Accounting Officer, for a detailed discussion of our financial results. David?

  • David Borges - Chief Accounting Officer, Vice President - Finance, Treasurer

  • Thanks, Greg.

  • Our third-quarter results reflect continued progress in the commercial launch of YARTEMLEA, along with actions to strengthen our capital structure and enhance our financial flexibility.

  • Excluding non-cash remeasurement adjustments associated with our financial instruments, non-GAAP adjusted net income increased 161% from the second quarter, reflecting continued improvement in our financial performance.

  • YARTEMLEA continued to demonstrate strong commercial momentum in the third quarter, with gross-product revenues increasing to $41.8 million compared to $32.2 million in the second quarter.

  • Net product revenues increased to $35.9 million, up from $28.5 million in the second quarter.

  • Gross-to-net adjustments were 14% in the third quarter compared with 11.5% in the second quarter and remained within our expectations.

  • These adjustments consisted primarily of charge-backs and distribution fees, with the increase driven primarily by higher utilization of the 340B program.

  • Turning to our financial results, the net loss for the third quarter was $57.4 million or $0.79 per share compared to net income of $13.2 million or $0.18 per share in the second quarter.

  • Third-quarter results included a $62 million non-cash mark-to-market loss on the financial instruments associated with our 2029 convertible notes compared to an $11.5 million net non-cash gain in the second quarter, reflecting a $73.5 million swing in non-cash remeasurement.

  • These adjustments were driven, largely, by increases in our stock price in the third quarter. These non-cash adjustments do not affect our operating performance or liquidity and are excluded from our non-GAAP adjusted results.

  • Excluding non-cash remeasurements of embedded derivatives and other financial instruments, non-GAAP adjusted net income for the third quarter was $4.7 million or $0.06 per share compared to $1.8 million or $0.02 per share for the second quarter.

  • In June and July, we entered into two privately negotiated transactions to repurchase $30.5 million aggregate principal amount of our 2029 convertible notes for $60.2 million, plus accrued interest.

  • Both transactions closed in July, reducing the outstanding principal by 43%, from $70.8 million to $40.3 million.

  • These transactions also reduced future cash-interest expense and potential dilution, with the number of shares issuable upon conversion declining from 11.4 million to 6.5 million.

  • We may opportunistically repurchase additional notes in the future, depending on market conditions and other considerations.

  • In connection with the second tranche of these repurchases, involving $14.5 million in principal, we recorded a $1.9 million loss in the third quarter, reflecting the extinguishment of the repurchased notes and the associated embedded-derivative liability.

  • As of September 30, 2026, we had $95.3 million in cash and investments. And net cash provided by operations in the third quarter was $13.3 million. Our cash balance reflects the $60.2 million paid to repurchase a portion of the 2029 convertible notes.

  • Total operating expenses from continuing operations before interest and other income were $31.4 million, an increase of $3 million from the second quarter.

  • Under our transition-services agreement with Novo, we continue to receive reimbursements for incurred cost, including third-party expenses and internal personnel cost.

  • We also recognized $459,000 in reimbursements for zaltenibart inventory transferred during the quarter, which was recorded in other income.

  • Interest expense was $6.2 million, consisting primarily of the DRI royalty obligation and interest on the 2029 convertible notes.

  • Excluding the OMIDRIA royalty obligation to DRI, which is fully offset by amounts received from Rayner and, therefore, has no economic impact on Omeros, as well as non-cash amortization of debt issuance costs and discounts, contractual-cash interest expense was $1.1 million.

  • This represents a decrease of $600,000 from the second quarter, reflecting the impact of our repurchases of the 2029 convertible notes.

  • Interest and other income totaled $1.9 million in the third quarter. And income from discontinued operations was $6.5 million in the third quarter, which was consistent with the second quarter.

  • Because US OMIDRIA royalties are passed directly to DRI, fluctuations in these payments have no impact on our cash position.

  • Now, let me turn to our expectations for the fourth quarter of 2026:

  • We expect total operating expenses from continuing operations to be slightly higher than in the third quarter.

  • Research and development expenses are expected to increase, primarily due to higher spending on YARTEMLEA and our OMS805 OncotoX-AML program.

  • Sales and marketing expenses, also, are expected to increase, reflecting continued investment in YARTEMLEA, commercial infrastructure, marketing, and launch activities.

  • Interest and other income is expected to increase in the fourth quarter, primarily reflecting anticipated inventory reimbursements from Novo.

  • Interest expense is expected to be approximately $6 million, reflecting the reduction in outstanding debt, following the 2029 note repurchases. This estimate excludes potential non-cash adjustments related to the OMIDRIA royalty obligation.

  • Income from discontinued operations is expected to be between $5 million and $6 million, excluding non-cash remeasurement adjustments related to the OMIDRIA contract-royalty asset.

  • And, finally, our reported results will continue to reflect non-cash mark-to-market adjustments on the embedded derivative associated with our 2029 convertible notes.

  • Again, these adjustments can be volatile, driven, primarily, by changes in our stock price; and are excluded from our non-GAAP adjusted results.

  • And, with that, I will turn it back over to Greg.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Thank you, David.

  • And, operator, would you please open the call to questions?

  • Operator

  • We will now begin the question-and-answer session.

  • (Operator Instructions)

  • Serge Belanger, Needham.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Hi, Serge. Hello?

  • Operator

  • Serge, a reminder to kindly unmute yourself.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Operator, why don't we move on? And, if Serge jumps back in the queue, happy to speak with him.

  • Operator

  • Olivia Saunders, Cantor Fitzgerald.

  • Olivia Saunders - Analyst

  • Hi. Good afternoon. Thank you for the question.

  • Just want to make sure you guys can hear me?

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Hi, Olivia. We can hear you. Thank you.

  • Olivia Saunders - Analyst

  • All right. Perfect.

  • Hoping to dig into the launch dynamics a little bit more. Just given the acceleration that you saw last quarter versus this one, can you talk about the pace of adoption that you are expecting from here? And how are you thinking about how much utilization NTAP will actually drive in the fourth quarter?

  • And, anything you can say, at this point, around whether you are seeing a noticeable change in utilization or the pace of hospital adoption since that October 1 effective NTAP went into place?

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Yes. Thanks.

  • First, as we have said previously, we will not really be guiding to fourth-quarter results, other than, I think, to underscore what I said in the opening comments, which is that the momentum of growth has continued in Q4. So we are seeing continued growth in Q4.

  • With respect to the impact of NTAP, it is interesting that NTAP -- obviously, important to us; obviously, important to you, as well -- but it is interesting to us how physicians and, frankly, institutions are not widely aware of the NTAP Award for YARTEMLEA.

  • And this is one of our current areas of focus, which is to make sure that that understanding of YARTEMLEA's receipt of NTAP and the importance to the inpatient facilities -- and, specifically, Medicare patients -- how that is important to those facilities, as well.

  • Bill, do you have any other comment you want to add on that about NTAP?

  • Bill Woodman - Chief Commercial Officer

  • Yeah.

  • I have experience with NTAP with other companies and other drugs. And it is a learning process that you have to teach people on how to take advantage of that situation.

  • We have a booth coming up here at ASH that will highlight the NTAP changes and what is available to these accounts.

  • It is interesting to note that the largest growth in allogeneic transplant is patients over 65. And, actually, at a recent meeting -- actually, a couple days ago -- they talked about the silver tsunami they are expecting to see, as these treatments for AML, in particular, get better and better.

  • They can get more and more patients to transplant. And they expect to transplant more and more patients over 65.

  • So NTAP is going to do nothing but help us, as we move into that growth. And we're looking forward to educating as many people as we can to take advantage of this program.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • So what we see is Medicare, now, representing about 30% of allogeneic transplants. We would expect, as Bill just said, that number to grow.

  • I think it's also important to recognize that, while we're talking about a Medicare segment of the population, the allogeneic-transplant population only, once again, that -- institutions, transplant centers start using the drug for their Medicare patients.

  • I expect that they will see the response. And that just causes continued expansion throughout each of those centers, transplant patients, and TMA patients more broadly.

  • Olivia Saunders - Analyst

  • Okay. Very helpful.

  • And if I could ask a follow-up on gross to net: Where do you ultimately expect that to shake out, as you shift patients to the outpatient setting, moving forward?

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Yeah. That's a great question.

  • I don't think that we have shared a target number there. But, yeah, I think that we are approaching it more quickly than we had anticipated; meaning, anticipated approaching where we think that cap will be.

  • And I think that is reflective of the shift, obviously, given that this increase in gross to net is, as I said, almost exclusively due to 340B. This is a very encouraging signal to us of transfer from inpatient to outpatient.

  • And, again, for us, as you know but just to make sure everybody understands, the 340B discount has no impact on our ASP. This is a government-mandated discount, not one that the company is taking independently.

  • So it has no impact on our ASP, which, overall, then, really, just exemplifies, I think, the expansion from inpatient to outpatient, which, as I think we pointed out, benefits not only the patient but the centers, as well.

  • So I think that, overall, Olivia, I would think -- and, again, I am giving you a very soft number here -- but somewhere in the high-teens would be what we would think we might be approaching at some point.

  • But to jump from 11.5% to 14% from the prior quarter to this quarter, we see as a resounding acknowledgement, recognition, and -- of the importance of the drug and moving it into the outpatient setting.

  • It also underscores, I think, the safety of the drug, certainly -- the perceived safety of the drug -- by the physicians that they are willing to move this out of the inpatient setting where there is, as you know, very regular, constant monitoring and into the outpatient setting.

  • I think it speaks really strongly for the potential of YARTEMLEA and the safety of YARTEMLEA from -- as well, clearly, of its efficacy.

  • Did that help?

  • Olivia Saunders - Analyst

  • Yeah. That is great. Thank you, Greg. Really appreciate that color.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Yeah. You are welcome, Olivia. Thank you.

  • Operator

  • Serge Belanger, Needham.

  • Serge Belanger - Analyst

  • All right. Good evening. Can you guys hear me now?

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • We can. Hi, Serge. How are you?

  • Serge Belanger - Analyst

  • I am good. Sorry. I am technically challenged. Anyway, a couple questions on YARTEMLEA, to start off with.

  • Can you maybe talk about the volume of vials in the inpatient setting versus the outpatient setting that you are currently seeing?

  • And then, secondly, just curious, what is the average price do you estimate for on a per-patient basis? Because I think, in the past, you have talked about some patients being treated on a weekly basis and some others on a twice-weekly basis.

  • So just curious where that has settled and what revenues you are seeing per patient on YARTEMLEA.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Understood the question.

  • We haven't shared the vial split between in and outpatient and so we will not today, other than to say that the outpatient use has meaningfully increased.

  • With respect to utilization per course, it's interesting. I think we're seeing a shift. And, again, we don't have great access because of HIPAA and all of the confidentiality components around HIPAA.

  • We don't have, really, great visibility into patient-level data, patient-level information. But what I think we are seeing is an increase in the use of twice-weekly early on, which, as we think about it and, probably, as you think about it, that probably ties to the increased outpatient use that we're seeing, as well.

  • So hit them hard early and then, move them to the outpatient setting, where you can treat them on an outpatient basis.

  • The average use for our study and for our EAP were in the 8 to 10 vial per course range. Having said that, I think we've noted before, we had some patients -- primarily, pediatric patients -- who had remained on the drug for a very long time: beyond a year.

  • And, when we went to run that down to see why these patients had been kept on the drug for such a lengthy time, the question was, gee, are you not seeing the response that you are hoping to see with the drug?

  • The answer was quite the opposite. It's, no, drug's working great. This is why we have the patient on and we're keeping the patient on because we are concerned, always, about relapse.

  • So, obviously, the fact that we were running this through the expanded-access program, where we were providing drug for free, I would expect, had a very large impact on their ability to use it for that extensive amount of time.

  • But I think it does underscore that, when one you -- when one does -- and this is what we hear from experts so I am only relaying what I'm hearing -- but, when we hear that -- the benefit-risk balance in the use of YARTEMLEA, it's so heavily weighted toward the benefit that a number of physicians are reticent to take their patients off YARTEMLEA, simply because they want to keep them covered, protected, in the event of a relapse.

  • So I know I'm not answering your question, specifically, on what are the numbers. I can tell you that we don't have those tightly because those are, really, patient-level data that we just don't access. But I'm trying to give you some color, Serge, as to what we're hearing and what we're seeing.

  • Does that help?

  • Serge Belanger - Analyst

  • Yeah. Thank you. And, maybe, just one last one:

  • Looks like you have reimbursement and access, more or less, buttoned up here with the NTAP, the J-code, and some clarity with the 340B coverage.

  • Just curious if you will be in a position to provide guidance for 2027.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • We will begin providing guidance, at some point, in 2027, I expect. We just want to get a sense of how the overall sales are looking.

  • We are very pleased with what we are seeing. But what we do not want to do is get out ahead of ourselves and guide, when we really do not have the data to back up that.

  • It is one thing when estimates are provided by analysts, like yourself and others. It is another thing when we provide those estimates and then there's this -- those are viewed a little differently.

  • I will ask Bill about his comments, just on the utilization of the drug, as well, to see, Bill, if you have any other thoughts for Serge on utilization and vials per course.

  • Bill Woodman - Chief Commercial Officer

  • Yeah. I think you can see -- I think the biggest thing you can see is that shift to the outpatient is the increase in our 340B discount.

  • Whenever you launch in an acute disease, generally, you get the sickest of the sick first. ANd the great thing about YARTEMLEA is it works.

  • So they are treating the sickest sick on the inpatient side. They get more comfortable with it. Those patients leave the ICU. They go home. They get treated in their outpatient center.

  • And you can see that shift, as we go from quarter to quarter. And it is going to get nothing but better from there. We have many, many examples of people walking out of ICUs that they did not expect to happen.

  • So the good news is the drug is working. That shift, over time, as Greg alluded to, will probably increase, as people get more and more comfortable with it.

  • We have had situations where people have gone home to, just, their regular community-based hospital and continue to receive treatment. And that hospital is not a transplant center and have had no problem infusing, billing for, getting paid for the drug.

  • And so all these things are good signs to see that we are going to treat more and more patients in the outpatient side.

  • And then, as people get really comfortable with it, they will treat them on the outpatient side before they come in. And you will get a more consistent basis, over time, as you treat those patients before they get into trouble.

  • Right now, we are really treating the patients who are already in trouble. And we want to move that to the outpatient side.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Thanks, Bill.

  • So, once we have a better sense of all of those factors that Bill just touched on, we'll be more comfortable providing guidance. Until then, really, we are still sifting through data, as you are.

  • All I can say is the data that we see -- all of the data that we see -- are highly encouraging for the potential of YARTEMLEA in TA-TMA.

  • Bill Woodman - Chief Commercial Officer

  • Yeah. And, from a marketing perspective, we grew in every metric that we measured. We cannot be happier. The momentum is easy to see and feel, especially at recent medical meetings.

  • We are built for the long-term sustained growth. And we are going to ensure to invest in ways that this education occurs and people are more ready to treat these patients as quickly as possible.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • And I think that is underscored by, just, the focus that we went through in the prepared comments about the number of education positions -- educator positions that we have added. We have added 10 positions in the last six weeks.

  • And this is not driven by a concern that we are not educating enough. It is driven by the customer requests and customer need for the education.

  • So we are not trying to fix a problem by adding these educators. We are addressing a need that is being voiced by the transplant physicians, pharmacists, nurses, the end users, or the end-use administrators of the drug.

  • And I think that is an important distinction.

  • Operator

  • Steve Brozak, WBB.

  • Steve Brozak - Analyst

  • Hey, thanks for taking the question. Actually, I do have two.

  • Just to reiterate: You are not just cash flow break-even, you actually are cash flow-positive right now? You can repeat anything you've got because the only question becomes on the treatment of the derivative.

  • When do you expect that, by the way, to clear up?

  • And I've got a really significant question after this.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Well, I'll start with the last question first.

  • As soon as we get rid of the convert overhang, which -- we've taken a large part of that away through the repurchase of the converts. But, however we eliminate the remainder of that convert, that derivative will disappear with it.

  • With respect to your question about cash flow-positive, yes, we're $13.3 million cash flow-positive from operations this quarter.

  • Frankly, we were also cash flow-positive last quarter in our first full quarter of the launch, which we think is pretty remarkable.

  • We don't frankly expect that -- I know we've said we won't guide for Q4 but I think it's pretty clear that we don't expect that's going to change in Q4.

  • So this is where we stand. And this is how we're able to continue funding all of the other things that we're doing with the company. That, and what we expect will be the revenues coming from the Novo transaction.

  • All of this, I think, puts us in a very strong financial position across the company.

  • David, any other comments on that or color you want to add?

  • David Borges - Chief Accounting Officer, Vice President - Finance, Treasurer

  • No. I would echo what you said.

  • We've seen a nice path from $4.1 million of cash from ops in Q2 to over $13 million this quarter; and see that trend continuing, going forward, as you said.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • And, as we move, really, to what we expect will be standard of care, at some point, that threshold is reached and the use of the drug, just, I think, will increase even more so.

  • But, that, again, is my personal view.

  • Steve Brozak - Analyst

  • Okay. That brings me to a perfect segue here:

  • 30 years ago, I worked on a private transaction and a public offering for a company called Alexion. And just about 20 years ago (multiple speakers) --

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Never heard of them. I have never heard of them.

  • Steve Brozak - Analyst

  • Good. Just keep to that.

  • And they came up with a product, eculizumab, a complement product, obviously. And I am sure you have looked at what they did and how they grew their revenue.

  • How would you compare your approach with what they did? Because, obviously, it is a good historical mark. Not saying it is identical but it is a good historical mark.

  • And I will jump back in the queue with that open question. How is that?

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Yeah. Look, I understand the question. I understand, I think, the relevance of it and the curiosity about it.

  • Remember that these were very different products, right? When SOLIRIS or eculizumab was launched, that initial indication was for PNH, paroxysmal nocturnal hemoglobinuria, which is a chronic disease.

  • What we are treating is TA-TMA, which is an acute disease. So, duration of therapy, obviously, limited.

  • One is, we're treating until we cure the patient, which is, to the best of our knowledge, relatively quickly. And eculizumab was used chronically so treating, effectively, for that patient's life.

  • The pricing, we have looked at that. Obviously, we looked at that, as we were determining where to price YARTEMLEA.

  • And the course of therapy for a year, pretty similar. Ours, probably less, as you might imagine, for an acute or episodic treatment versus chronic.

  • So there are real differences there, Steve. But, having said that, I think, as you may have anticipated, certainly, we've looked at that.

  • The eculizumab numbers aren't readily available for US. They need to be implied from the worldwide sales. But for third quarter of their sales versus third quarter of our sales -- our sales, US only -- we exceed their third -quarter worldwide sales, at least.

  • I think that's my understanding. Bill, is that correct?

  • Bill Woodman - Chief Commercial Officer

  • That is correct. Yeah.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Yeah. And then, when you look at the first three quarters of sales, again, implied in the US, based on subsequent splits, in the US, we're doing about 60% better in net revenues than they did in their third quarter. So we're pleased with how we're stacking up.

  • That does not, in any way, predict, guide, what we're going to do in the future. But, obviously, we're happy with where we stand.

  • And I think, yeah, your question was an interesting one. Of course, we look at these things. We don't only look at eculizumab. We look, really, at all complement inhibitors. That includes pegcetacoplan or EMPAVELI. That includes even ravu. And it also includes defibrotide.

  • So we have a pretty good set of metrics against which to assess ourselves and YARTEMLEA's growth and uptake. And I think, yeah, we are quite pleased with it, particularly given what I said about chronic versus episodic use.

  • But I don't know. I am guessing that answered your question. But, if not, do you (multiple speakers) --

  • Steve Brozak - Analyst

  • No. No. It does. They say history doesn't repeat itself but it does rhyme so you have answered it. Thank you.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Good. Thank you.

  • Operator

  • There are no further questions at this time.

  • I will now turn the call back to Dr. Demopulos for closing remarks.

  • Gregory Demopulos - Chairman, Chief Executive Officer

  • Thank you, operator. And thanks everyone for your time.

  • YARTEMLEA's approval really turned years of scientific work into a treatment for patients who urgently needed one. Its adoption is now helping fund, as we discussed, the next chapter of that work, extending its reach and advancing therapies for other serious diseases.

  • We are excited about YARTEMLEA's expanding potential and confident in our science and our team's ability to develop new medicines that improve patients' lives and build lasting value for our shareholders.

  • So thank you, again, all, for joining this afternoon and for your continued support. We look forward to speaking with you, again. Thank you.

  • Operator

  • This concludes today's call. Thank you for attending. You may now disconnect.